Dr. Di Bisceglie is professor of Internal Medicine and chairman of the Department of Internal Medicine at Saint Louis University. He received his medical degree from the University of the Witwatersrand in Johannesburg, South Africa, where he completed his training in internal medicine. He then received training at the National Institutes of Health (NIH) as a fellow in the Liver Diseases Section of NIDDK where he subsequently became a senior investigator and the Chief of the Liver Diseases Section. Dr. Di Bisceglie moved to Saint Louis University in 1994 initially as Associate Chairman of Internal Medicine, then as Chief of Hepatology and most recently as Department Chairman.
Dr. Di Bisceglie's research focuses on viral hepatitis, particularly aspects of its treatment and its relationship with hepatocellular carcinoma. He has spent his career involved in the development of new therapies for chronic hepatitis B, hepatitis D, and hepatitis C beginning in 1983 in South Africa when he was part of the team to first administer recombinant alpha interferon to patients with chronic hepatitis B. At the NIH, he was among the first to test the effect of alpha interferon in the management of chronic non-A/non-B hepatitis. He has utilized clinical samples and data obtained from patients participating in various research trials to study the mechanisms of action of therapy and to examine the pathogenesis of these various forms of chronic viral hepatitis.
Dr. Di Bisceglie has authored nearly 400 articles, book chapters, and review papers on the subject of viral hepatology and liver disease and is co-editor with Drs. Bacon, O'Grady and Lake of the second edition of Comprehensive Clinical Hepatology. Dr. Di Bisceglie has served on a number of NIH study sections, as a member of the FDA Blood Product Advisory Committee and as a member of the Translational Research Working Group of the National Cancer Institute. Most recently Dr. Di Bisceglie has served as Chairman of the Steering Committee of HALT-C Trial Group from 1999 to 2009.
Dr. Di Bisceglie has been a member of AASLD since 1989 and has attended every annual meeting since 1984. He has served the association in a number of capacities including participation as a member of the research committee, clinical research committee, strategic alliance task force, and public policy committee. He has chaired the clinical research committee, public policy committee and a number of abstract selection committees and was elected to the nominating committee in 2001. He has been co-organizer of three AASLD single topic conferences on Hepatocellular Carcinoma, new therapeutic agents for hepatitis C and End-Points in Clinical Trials for Hepatocellular Carcinoma. Dr. Di Bisceglie was associate editor of HEPATOLOGY from 1991 to 1995 and has served as a member of its editorial board.
Conflict of Interest
Dr. Adrian M. Di Bisceglie serves on the advisory boards of Bristol-Myers Squibb, Merck, Pharmasset, Roche/Genentech, Salix, Tibotec, and Vertex. He also serves on the Data Safety Monitoring Board for Bayer. Dr. Di Bisceglie receives grant and research support from Abbott, Anadys, Bristol-Myers Squibb, Gilead, GlobeImmune, Idenix, Pharmasset, Roche/Genentech, Transgene, Tibotec, and Vertex.